Skip to main content

Dermatology

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.



Rheumatic and autoimmune patients were not

Read Article
psor.elb_.jpg

Spesolimab, an IL-36 Blocker, in Pustular Psoriasis

Jan 03, 2022

The NEJM has published the results of a phase 2 randomized trial showing that the use of an interleukin-36 receptor inhibitor, spesolimab, resulted in rapid improvement of generalized pustular psoriasis (at 1 week), but that adverse events and infections were of concern with 12 weeks of

Read Article
FDA.approved.jpg

Best of 2021: FDA Approves Anifrolumab in SLE

Dec 24, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article
fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations

Read Article
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
nobel-prize-1356450__180.jpg

Pain is the Focus of the 2021 Nobel Prize in Medicine

Dec 08, 2021

The 2021 Nobel Prize in Medicine and Physiology was jointly awarded to Drs. David Julius and Ardem Patapoutian for their discoveries of receptors for temperature and touch. Their work on neural signaling of heat and touch (tactile) relate to many physiologic conditions including chronic pain

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016. Now the 2021

Read Article
ICYMI: Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.https://t.co/XEJMyvKDnx

Dr. John Cush @RheumNow( View Tweet )

Nov 27, 2021
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but may be residual confounding due to burden disease/comorbidities. Abstr#1942 #ACR21 @RheumNow https://t.co/UzOwuKKFmX
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
*️⃣Abst#1800 observed that a changing pattern of purine, lipid, & amino acid metabolites occurred during transition from PsO to PsA. *️⃣Compared to pts w/ Pso that didn't progress to PsA, those that progressed had elevated levels of guanine! Potential biomarkers? #ACR21 @RheumNow https://t.co/iQh1ZapDMB
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 09, 2021
Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO and PsA diagnoses. No other variables, including BSA, were associated with time to transition @RheumNow #ACR21 Abst#1798 https://t.co/fLPBHKAMAc
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 09, 2021
Can we predict which PsO pts will develop PsA? Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA. Abs#1774 #ACR21 @RheumNow https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
ACR Best

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Nov 08, 2021

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Read Article
Cush ACR learning computer online

Day 2 Report from ACR21

Nov 08, 2021

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
Dr. Fujimoto provides a wonderful overview of skin findings in DM by antibody #ACR21 #ACRAmbassador https://t.co/KpOsgKPU7j
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21 ⭐️This disease featuring purple-red papulosquamous eruptions, on the hands and elsewhere, can have preceding painless erosive symmetrical arthritis at the DIPs, and has a 30% malignancy risk. ➡️Multicentric Reticulohistiocytosis @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 08, 2021
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics ⭐️HR 1.39 ⭐️retrospective cohort study w/ >1300 cases Abs#1355 #ACR21 #ACRBest @RheumNow https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 08, 2021
Psoriasis can be diagnosed at any time of axSpA follow up. Incidence of PsO ⬆️from 16.8% to 26.8% after 6 years Patients with PsO had more peripheral arthritis and higher BMI Abs#1311 @RheumNow https://t.co/IrvHiFqr2m https://t.co/lqCVcF81zA
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 08, 2021
Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study evaluated 240 patients with axSpA ⭐️Imaging of the SIJ and spine DOES NOT differ in Ps axSpA or axSpA associated with iritis or colitis Abst# 0902 #ACR21 #ACRBest @RheumNow https://t.co/Y2bRlysXI5
swethaann23 @swethaann23( View Tweet )
Nov 07, 2021
Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH
Richard Conway @RichardPAConway( View Tweet )
Nov 07, 2021
lupus.nephritis.immunofluorescence.jpg

Serologically Active, Clinically Quiescent SLE

Nov 01, 2021

Lupus management is guided by assessment of both clinical and serologic features; but what happens with the patient with systemic lupus erythematosus (SLE) serologically active, but clinically quiescent (SACQ)?  A large cohort study shows that nearly one-third of such patients may flare and

Read Article
×